GSK plc (GSK)
Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-29 |
| Earnings Call | 2025-10-29 |
| Avg EPS Estimate | 0.6146 |
| Low EPS Estimate | 0.5886 |
| High EPS Estimate | 0.6405 |
| Revenue | |
| Avg Revenue Forecast | 8,412,104,840 |
| Low Revenue Forecast | 8,167,872,890 |
| High Revenue Forecast | 8,572,314,000 |
GSK Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $3,305,999,872 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.544 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 0.836 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $17,749,999,616 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
GSK Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $9,518,999,552 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $7,792,000,000 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $3,749,499,904 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 72.43% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 32.61% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 17.08% | Net profit margin, which reflects overall profitability. |
GSK Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 112.68% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $17,749,999,616 | Used together with cash and EBITDA to assess debt-paying ability. |
GSK Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 6.70% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for GSK (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $46.69 | Latest stock trading price |
| Price Target (High) | $58 | Analyst highest expected price |
| Price Target (Low) | $36 | Analyst lowest expected price |
| Price Target (Average) | $47.11 | Average target price across analysts |
| Price Target (Median) | $45.3 | Median of target prices |
| Average Rating Score | 3 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | hold | Consensus rating |
| Analyst Coverage Count | 8 | Number of analysts providing estimates |
| Cash Holdings | $3,305,999,872 | Total cash held by the company |
| Cash per Share | $0.82 | Cash value per outstanding share |
| Total Debt | $17,749,999,616 | Company's total debt |
| Quick Ratio | 0.544 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 0.836 | Overall short-term liquidity |
| Debt/Equity Ratio | 112.68% | Leverage ratio: Debt / Equity |
| EBITDA | $9,518,999,552 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $32,166,000,640 | Total company revenue |
| Revenue per Share | $15.82 | Total revenue divided by shares outstanding |
| Gross Profit | 72.43% | Revenue minus cost of goods sold |
| Return on Assets | 7.13% | Net income / Total assets |
| Return on Equity | 41.52% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 6.70% | Year-over-year revenue growth |
| Gross Margin | 72.43% | Gross profit / Total revenue |
| EBITDA Margin | 29.59% | EBITDA / Revenue |
| Operating Margin | 32.61% | Operating income / Revenue |
| Profit Margin | 17.08% | Net income / Revenue |
| Free Cash Flow | $3,749,499,904 | Cash left after capital expenditures |
| Operating Cash Flow | $7,792,000,000 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |